Metformin suppresses adipogenesis through both AMP-activated protein kinase (AMPK)-dependent and AMPK-independent mechanisms
Open accessThe DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Abstract
People with Type 2 diabetes mellitus (T2DM) have reduced bone mineral density and an increased risk of fractures due to altered mesenchymal stem cell (MSC) differentiation in the bone marrow. This leads to a shift in the balance of differentiation away from bone formation (osteogenesis) in favour of fat cell development (adipogenesis). The commonly used anti-diabetic drug, metformin, activates the osteogenic transcription factor Runt-related transcription factor 2 (Runx2), which may suppress adipogenesis, leading to improved bone health. Here we investigate the involvement of the metabolic enzyme, AMP-activated protein kinase (AMPK), in these protective actions of metformin. The anti-adipogenic actions of metformin were observed in multipotent C3H10T1/2 MSCs, in which metformin exerted reciprocal control over the activities of Runx2 and the adipogenic transcription factor, PPARγ, leading to suppression of adipogenesis. These effects appeared to be independent of AMPK activation but rather through the suppression of the mTOR/p70S6K signalling pathway. Basal AMPK and mTOR/p70S6K activity did appear to be required for adipogenesis, as demonstrated by the use of the AMPK inhibitor, compound C. This observation was further supported by using AMPK knockout mouse embryo fibroblasts (MEFs) where adipogenesis, as assessed by reduced lipid accumulation and expression of the adipogeneic transcription factor, C/EBPβ, was found to display an absolute requirement for AMPK. Further activation of AMPK in wild type MEFS, with either metformin or the AMPK-specific activator, A769662, was also associated with suppression of adipogenesis. It appears, therefore, that basal AMPK activity is required for adipogenesis and that metformin can inhibit adipogenesis through AMPK-dependent or -independent mechanisms, depending on the cellular context.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Role of AMP-Activated Protein Kinase in Mechanism of Metformin Action
Zhou, G., Myers, R., Li, Y., Chen, Y., Shen, X., Fenyk-Melody, J., Wu, M., Ventre, J., Doebber, T., Fujii, N., et al. (2001) · Journal of Clinical Investigation · doi:10.1172/jci13505 · Cited by 5,652
Cellular and molecular mechanisms of metformin: an overview
Viollet, B., Guigas, B., Garcia, N. S., Leclerc, J., Foretz, M., & Andreelli, F. (2012) · Clinical Science · doi:10.1042/cs20110386 · Cited by 1,720
Self-citationRegulated expression of three C/EBP isoforms during adipose conversion of 3T3-L1 cells.
Cao, Z., Umek, R. M., & McKnight, S. L. (1991) · Genes & Development · doi:10.1101/gad.5.9.1538 · Cited by 1,663
LKB1 is the upstream kinase in the AMP-activated protein kinase cascade
Woods, A., Johnstone, S. R., Dickerson, K., Leiper, F. C., Fryer, L. G. D., Neumann, D., Schlattner, U., Wallimann, T., Carlson, M., & Carling, D. (2003) · Current Biology · doi:10.1016/j.cub.2003.10.031 · Cited by 1,650
AMP-activated protein kinase induces a p53-dependent metabolic checkpoint
Jones, R. G., Plas, D. R., Kubek, S., Buzzai, M., Mu, J., Xu, Y., Birnbaum, M. J., & Thompson, C. B. (2005) · Molecular Cell · doi:10.1016/j.molcel.2005.03.027 · Cited by 1,619
Hawley, S. A., Pan, D. A., Mustard, K. J., Ross, L., Bain, J., Edelman, A. M., Frenguelli, B. G., & Hardie, D. G. (2005) · Cell Metabolism · doi:10.1016/j.cmet.2005.05.009 · Cited by 1,589 · cited 2×
“AMPK can also be phosphorylated and activated at Thr172 by calcium/calmodulin-dependent protein kinase kinase (CaMKK) in a Ca 2 þ -dependent, AMP-independent manner (Hawley et al., 2005).”
BackgroundEl-Mir, M.-Y., Nogueira, V., Fontaine, E., Avéret, N., Rigoulet, M., & Leverve, X. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.275.1.223 · Cited by 1,399 · cited 1×
“Metformin interferes with oxidative phosphorylation in the mitochondria by inhibiting complex I in the electron transport chain, although the exact mechanism of inhibition is not yet known (El-Mir et al., 2000,Lantier et al., 2014).”
BackgroundForetz, M., Hébrard, S., Leclerc, J., Zarrinpashneh, E., Soty, M., Mithieux, G., Sakamoto, K., Andreelli, F., & Viollet, B. (2010) · Journal of Clinical Investigation · doi:10.1172/jci40671 · Cited by 1,181 · cited 2×
“…cell types; however a requirement of AMPK for the therapeutic actions of metformin has been questioned following genetic loss of function experiments that demonstrated AMPK-independent mechanisms of action of metformin during the inhibition of hepatic gluconeogenesis (Foretz et al., 2010).”
BackgroundSelf-citationChronic activation of AMP kinase results in NRF-1 activation and mitochondrial biogenesis
Bergeron, R., Ren, J. M., Cadman, K. S., Moore, I. K., Perret, P., Pypaert, M., Young, L. H., Semenkovich, C. F., & Shulman, G. I. (2001) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.2001.281.6.e1340 · Cited by 561
AMPK: positive and negative regulation, and its role in whole-body energy homeostasis
Hardie, D. G. (2015) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2014.09.004 · Cited by 485 · cited 1×
“AMPK is a heterotrimeric serine/threonine protein kinase that acts as a cellular energy sensor due to its ability to be activated by an increase in the AMP-ATP ratio, which leads to phosphorylation of Thr172 on AMPK a by liver kinase B1 (LKB1) (Hardie, 2015,Woods et al., 2003).”
BackgroundVazquez-Martin, A., Oliveras-Ferraros, C., & Menendez, J. A. (2009) · Cell Cycle · doi:10.4161/cc.8.1.7499 · Cited by 250 · cited 2×
“Moreover, metformin has been shown to inhibit the activation of the p70S6K pathway independently of AMPK (Vazquez-Martin et al., 2009) in tumour cells and p70S6K has been shown to be required for the growth hormone-dependent adipose conversion of 3T3-F442A preadipocytes (Yarwood et al.”
BackgroundAMPK controls exercise endurance, mitochondrial oxidative capacity, and skeletal muscle integrity.
Lantier, L., Fentz, J., Mounier, R., Leclerc, J., Treebak, J. T., Pehmøller, C., Sanz, N., Sakakibara, I., Saint‐Amand, E., Rimbaud, S., et al. (2014) · The FASEB Journal · doi:10.1096/fj.14-250449 · Cited by 228 · cited 1×
“Metformin interferes with oxidative phosphorylation in the mitochondria by inhibiting complex I in the electron transport chain, although the exact mechanism of inhibition is not yet known (El-Mir et al., 2000,Lantier et al., 2014).”
BackgroundSelf-citationOCT1 expression in adipocytes could contribute to increased metformin action in obese subjects
Moreno-Navarrete, J. M., Ortega, F. J., Rodríguez-Hermosa, J.-I., Sabater, M., Pardo, G., Ricart, W., & Fernández-Real, J. M. (2011) · Diabetes · doi:10.2337/db10-0805 · Cited by 100 · cited 1×
“…in more differentiated cell lines, such as pre-osteoblasts (Jang et al., 2011, Kanazawa et al., 2008,Cortizo et al., 2006), pre-adipocytes (Moreno-Navarrete et al., 2011,Lee et al., 2012), myoblasts (Longnus et al., 2005,Kobashigawa et al., 2014,Fulco et al., 2008) and neuronal mouse cell…”
BackgroundLongnus, S. L., Ségalen, C., Giudicelli, J., Sajan, M. P., Farese, R. V., & Van Obberghen, E. (2005) · Diabetologia · doi:10.1007/s00125-005-0016-3 · Cited by 58
Research works printed but not linked: 41
- Banerjee, 1997, Runt homology domain proteins in osteoblast differentiation: AML3/CBFA1 is a major component of a bone-specific complex, J. Cell Biochem., 66, 1, 10.1002/(SICI)1097-4644(19970701)66:1<1::AID-JCB1>3.0.CO;2-V · DOI · Paper page
- Bang, 2014, Convergence of IPMK and LKB1-AMPK signaling pathways on metformin action, Mol. Endocrinol., 28, 1186, 10.1210/me.2014-1134 · DOI · Paper page
- Chen, 2016, Fate decision of mesenchymal stem cells: adipocytes or osteoblasts?, Cell Death Differ., 0000023, 1128, 10.1038/cdd.2015.168 · DOI · Paper page
- Cool, 2006, Identification and characterization of a small molecule AMPK activator that treats key components of type 2 diabetes and the metabolic syndrome, Cell Metab., 3, 403, 10.1016/j.cmet.2006.05.005 · DOI · Paper page
- Cortizo, 2006, Osteogenic actions of the anti-diabetic drug metformin on osteoblasts in culture, Eur. J. Pharmacol., 536, 38, 10.1016/j.ejphar.2006.02.030 · DOI · Paper page
- Cusi, 1996, Metabolic effects of metformin on glucose and lactate metabolism in noninsulin-dependent diabetes mellitus, J. Clin. Endocrinol. Metab., 81, 4059
- Dowling, 2011, Understanding the benefit of metformin use in cancer treatment, BMC Med., 9, 33, 10.1186/1741-7015-9-33 · DOI · Paper page
- Fulco, 2008, Glucose restriction inhibits skeletal myoblast differentiation by activating SIRT1 through AMPK-mediated regulation of Nampt, Dev. Cell., 14, 661, 10.1016/j.devcel.2008.02.004 · DOI · Paper page
- Grey, 2007, The peroxisome proliferator-activated receptor-gamma agonist rosiglitazone decreases bone formation and bone mineral density in healthy postmenopausal women: a randomized, controlled trial, J. Clin. Endocrinol. Metab., 92, 1305, 10.1210/jc.2006-2646 · DOI · Paper page
- Habinowski, 2001, The effects of AICAR on adipocyte differentiation of 3T3-L1 cells, Biochem. Biophys. Res. Commun., 286, 852, 10.1006/bbrc.2001.5484 · DOI · Paper page
- Hothersall, 2013, Contemporary risk of hip fracture in type 1 and type 2 diabetes: a national registry study from Scotland, J. Bone Min. Res.
- Jang, 2011, Metformin induces osteoblast differentiation via orphan nuclear receptor SHP-mediated transactivation of Runx2, Bone, 48, 885, 10.1016/j.bone.2010.12.003 · DOI · Paper page
- Janghorbani, 2007, Systematic review of type 1 and type 2 diabetes mellitus and risk of fracture, Am. J. Epidemiol., 166, 495, 10.1093/aje/kwm106 · DOI · Paper page
- Jeon, 2003, Activation of peroxisome proliferator-activated receptor-gamma inhibits the Runx2-mediated transcription of osteocalcin in osteoblasts, J. Biol. Chem., 278, 23270, 10.1074/jbc.M211610200 · DOI · Paper page
- Kanazawa, 2008, Metformin enhances the differentiation and mineralization of osteoblastic MC3T3-E1 cells via AMP kinase activation as well as eNOS and BMP-2 expression, Biochem. Biophys. Res. Commun., 375, 414, 10.1016/j.bbrc.2008.08.034 · DOI · Paper page
- Kilpadi, 2014, Type 2 diabetes is associated with vertebral fractures in a sample of clinic- and hospital-based Latinos, J. Immigr. Minor Health, 16, 440, 10.1007/s10903-013-9833-5 · DOI
- Kim, 2012, Human mesenchymal stem cell differentiation to the osteogenic or adipogenic lineage is regulated by AMP-activated protein kinase, J. Cell Physiol., 227, 1680, 10.1002/jcp.22892 · DOI
- Kobashigawa, 2014, Metformin protects cardiomyocyte from doxorubicin induced cytotoxicity through an AMP-activated protein kinase dependent signaling pathway: an in vitro study, PLoS One, 9, e104888, 10.1371/journal.pone.0104888 · DOI · Paper page
- Lecka-Czernik, 2009, Bone as a target of type 2 diabetes treatment, Curr. Opin. Investig. Drugs, 10, 1085
- Lecka-Czernik, 2007, Activation of peroxisome proliferator-activated receptor gamma (PPARgamma) by rosiglitazone suppresses components of the insulin-like growth factor regulatory system in vitro and in vivo, Endocrinology, 148, 903, 10.1210/en.2006-1121 · DOI · Paper page
- Lee, 2011, AICAR, an activator of AMPK, inhibits adipogenesis via the WNT/beta-catenin pathway in 3T3-L1 adipocytes, Int. J. Mol. Med., 28, 65
- Lee, 2012, Metformin regulates glucose transporter 4 (GLUT4) translocation through AMP-activated protein kinase (AMPK)-mediated Cbl/CAP signaling in 3T3-L1 preadipocyte cells, J. Biol. Chem., 287, 44121, 10.1074/jbc.M112.361386 · DOI · Paper page
- Lee, 2014, The osteogenic or adipogenic lineage commitment of human mesenchymal stem cells is determined by protein kinase C delta, BMC Cell Biol., 15, 42, 10.1186/s12860-014-0042-4 · DOI
- Morrow, 2003, Direct activation of AMP-activated protein kinase stimulates nitric-oxide synthesis in human aortic endothelial cells, J. Biol. Chem., 278, 31629, 10.1074/jbc.M212831200 · DOI · Paper page
- Muruganandan, 2009, Adipocyte differentiation of bone marrow-derived mesenchymal stem cells: cross talk with the osteoblastogenic program, Cell Mol. Life Sci., 66, 236, 10.1007/s00018-008-8429-z · DOI · Paper page
- Nam, 2008, Compound C inhibits clonal expansion of preadipocytes by increasing p21 level irrespectively of AMPK inhibition, Arch. Biochem. Biophys., 479, 74, 10.1016/j.abb.2008.07.029 · DOI
- Pantovic, 2013, Coordinated time-dependent modulation of AMPK/Akt/mTOR signaling and autophagy controls osteogenic differentiation of human mesenchymal stem cells, Bone, 52, 524, 10.1016/j.bone.2012.10.024 · DOI · Paper page
- Reihill, 2007, AMP-activated protein kinase mediates VEGF-stimulated endothelial NO production, Biochem. Biophys. Res. Commun., 354, 1084, 10.1016/j.bbrc.2007.01.110 · DOI · Paper page
- Rosen, 2000, Molecular regulation of adipogenesis, Annu. Rev. Cell Dev. Biol., 16, 145, 10.1146/annurev.cellbio.16.1.145 · DOI · Paper page
- Saitoh, 2002, Regulation of an activated S6 kinase 1 variant reveals a novel mammalian target of rapamycin phosphorylation site, J. Biol. Chem., 277, 20104, 10.1074/jbc.M201745200 · DOI · Paper page
- Salminen, 2011, AMP-activated protein kinase inhibits NF-kappaB signaling and inflammation: impact on healthspan and lifespan, J. Mol. Med. Berl., 89, 667, 10.1007/s00109-011-0748-0 · DOI · Paper page
- Salt, 2012, Exploiting the anti-inflammatory effects of AMP-activated protein kinase activation, Expert Opin. Investig. Drugs, 21, 1155, 10.1517/13543784.2012.696609 · DOI · Paper page
- Schwartz, 2006, Thiazolidinedione use and bone loss in older diabetic adults, J. Clin. Endocrinol. Metab., 91, 3349, 10.1210/jc.2005-2226 · DOI · Paper page
- Shea, 2003, BMP treatment of C3H10T1/2 mesenchymal stem cells induces both chondrogenesis and osteogenesis, J. Cell Biochem., 90, 1112, 10.1002/jcb.10734 · DOI · Paper page
- Shockley, 2009, PPARgamma2 nuclear receptor controls multiple regulatory pathways of osteoblast differentiation from marrow mesenchymal stem cells, J. Cell Biochem., 106, 232, 10.1002/jcb.21994 · DOI · Paper page
- Sun, 2013, Osteoblast-targeted suppression of PPARgamma increases osteogenesis through activation of mTOR signaling, Stem Cells, 31, 2183, 10.1002/stem.1455 · DOI
- Tontonoz, 1994, mPPAR gamma 2: tissue-specific regulator of an adipocyte enhancer, Genes Dev., 8, 1224, 10.1101/gad.8.10.1224 · DOI · Paper page
- Tontonoz, 1994, Stimulation of adipogenesis in fibroblasts by PPAR gamma 2, a lipid-activated transcription factor, Cell, 79, 1147, 10.1016/0092-8674(94)90006-X · DOI · Paper page
- Vila-Bedmar, 2010, Adenosine 5'-monophosphate-activated protein kinase-mammalian target of rapamycin cross talk regulates brown adipocyte differentiation, Endocrinology, 151, 980, 10.1210/en.2009-0810 · DOI · Paper page
- Yarwood, 1999, Growth hormone-dependent differentiation of 3T3-F442A preadipocytes requires Janus kinase/signal transducer and activator of transcription but not mitogen-activated protein kinase or p70 S6 kinase signaling, J. Biol. Chem., 274, 8662, 10.1074/jbc.274.13.8662 · DOI
- Yeh, 1995, Cascade regulation of terminal adipocyte differentiation by three members of the C/EBP family of leucine zipper proteins, Genes Dev., 9, 168, 10.1101/gad.9.2.168 · DOI · Paper page
Cited by
Benefits of Metformin in Attenuating the Hallmarks of Aging
Kulkarni, A. S., Gubbi, S., & Barzilai, N. (2020) · Cell Metabolism · doi:10.1016/j.cmet.2020.04.001 · Cited by 766
Metformin induces lipogenic differentiation in myofibroblasts to reverse lung fibrosis
Kheirollahi, V., Wasnick, R. M., Biasin, V., Vazquez-Armendariz, A. I., Chu, X., Moiseenko, A., Weiss, A., Wilhelm, J., Zhang, J.-S., Kwapiszewska, G., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-10839-0 · Cited by 293
Metformin decelerates aging clock in male monkeys
Yang, Y., Lu, X., Liu, N., Ma, S., Zhang, H., Zhang, Z., Yang, K., Jiang, M., Zheng, Z., Qiao, Y., et al. (2024) · Cell · doi:10.1016/j.cell.2024.08.021 · Cited by 227
mTORC Inhibitors as Broad-Spectrum Therapeutics for Age-Related Diseases
Walters, H. E., & Cox, L. S. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19082325 · Cited by 85
Metadata
- Authors
- Chen, S. C., Brooks, R., Houskeeper, J., Bremner, S. K., Dunlop, J., Viollet, B., Logan, P. J., Salt, I. P., Ahmed, S. F., & Yarwood, S. J.
- Venue
- Molecular and Cellular Endocrinology
- Publisher
- Elsevier BV
- Published
- 2017-01
- Volume
- 440
- Pages
- 57-68
- ISSN
- 0303-7207 (ISSN-L)
- OpenAlex
- W2553954977
- Cited by
- 127
- References
- 14
- FWCI
- 5.72
- Type
- journal article
- Language
- en
- Update notices
- erratum (2017-03-05)
- Open access
- hybrid
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- creativecommons.org/licenses/by/4.0/ (vor)
- Funders
- Tenovus Scotland (S13/15)
- Diabetes UK Equipment Grant (11/0004309)
- British Heart Foundation Project Grant (PG/15/15/31316)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.